Riken Corporation

Suntory Limited

Other

Japan Science and Technology Agency

Japan Science and Technology Corporation

Research Development Corporation of Japan

Panasonic Corporation

Seiko Instruments Inc

Teijin Limited

Osaka University

Omron Healthcare Company Ltd.

Ge Healthcare Limited

Meiji Co., Ltd.

Osaka City University

University Public Corporation Osaka

Yasuyoshi Watanabe

Masaaki Suzuki

Bengt Langstrom

Hisashi Doi

Kei Mizuno

Yumiko Watanabe

Atsuo Hazato

Koji Kishimoto

Takao Shimizu

Osamu Hayaishi

Katsunori Tanaka

Hiroshi Naruse

Masashi Takesada

Kenji Fujii

Jun Suzuki

Kenichi Sato

Shingo Yamashita

Ryoji Noyori

Satoshi Obika

Hironori Omura

Masami Funakura

Takeshi Imanishi

Farhad Karimi

Takahiro Yamamoto

Tsuruo Nakayama

Yorimasa Suwa

Seiya Makino

Nobukazu Motojima

Etsuko Kanai

Hiroshi Morii

Youhei Jikihara

Takami Arai

Koichi Fukase

Hiroshi Kano

Gunnar Antoni

Jun Henmi

Noboru Yoshioka

Katsutoshi Sakurai

Miki Goto

Yoshihito Shigihara

Takeshi Kuboyama

Youhei Jikjhara

Tsuyoshi Tahara

Koki Hasegawa

Takumi Satoh

Yosuke Kataoka

Akihiro Ogura

Takumi Sato

Misato Takashima

Katsumi Akasaka

Miho Shukuri

Toshio Hayashi

Yuji Furuya

Hirotaka Onoe

Teruo Kitani

Julien Barletta

Hirohiko Kuratsune

Masaaki Tanaka

A fermented milk for improving autonomic nervous function containing at least one lactic acid bacterial species of the genusand its metabolite. The lactic acid bacterial species of the genusis selected from the group consisting ofsubsp.and. The lactic acid bacterial strain of the genusis preferablysubsp.OLL1073R-1(FERM BP-10741).

Fermented milk for improving autonomic nervous function

A fatigue degree determination device includes a fatigue degree determination unit. A first biological heart rate is acquired while a user is awake and at rest, based on a biological heart rate measured from the user. A second biological heart rate is acquired while the user is sleeping, based on the biological heart rate measured from the user. The fatigue degree determination unit determines a fatigue degree of the user, based on information read out from a storage medium, the first biological heart rate and the second biological heart rate. The storage medium stores the information in which a degree of change of one biological heart rate relative to the other biological heart rate of a biological heart rate while a person is awake and at rest and a biological heart rate while the person is sleeping and a fatigue degree are associated with each other.

Fatigue degree determination device, and fatigue degree determination method

An object of the present invention is to provide an albumin-sugar chain complex bound with a number of sugar chains sufficient for obtaining a sugar chain clustering effect while also being able to exist comparatively stably in the body. The present invention provides an albumin-sugar chain complex having five or more molecules of an asparagine-linked sugar chain bound per molecule of albumin; a carrier for selectively delivering a functional molecule to a target tissue in the body that contains the aforementioned albumin-sugar chain complex; and a bioimaging probe having the aforementioned albumin-sugar chain complex as an active ingredient thereof that is administered into the body of an animal.

Albumin-sugar chain complex

Disclosed are: labeled NSAIDs compounds which can be produced within a short time, can be used suitably for a PET method, and enable the imaging of cyclooxygenase-2; and a process for producing the labeled NSAIDs compounds. Specifically disclosed are isotope-labeled 2-arylpropionic acid compounds, each of which is a compound represented by general formula (1) (wherein Ar represents an aryl group which may have a substituent; Rrepresents anyone selected fromCH, CHF and CFF; and Rrepresents a hydrogen atom, or an alkyl group which may have a branch, wherein a compound wherein Ar is a benzene ring, RisCH, and Ris a hydrogen atom is excluded), or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof.

Isotope labeled 2-arylpropionic acid compounds and process for production of same, and molecular probe for positron emission tomography and method for imaging of cyclooxygenase and the like using same

Methods and reagents for transition metal-promoted carbonylation via isocyanate using carbon-isotope labeled carbon monoxide are provided. The resultant carbon-isotope labeled compounds are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits for PET studies are also provided.

Methods for carbon isotope labeling synthesis by transition metal-promoted carbonylation via isocyanate using azides and carbon-isotope monoxide

A human fatigue assessment device capable of performing highly accurate fatigue assessment is provided. The human fatigue assessment device includes: a physiological signal measuring unit which measures a pulse wave signal of a user; a feature value extracting unit which extracts first feature values each of which is obtained from a systolic posterior component of the pulse wave signal measured by the physiological signal measuring unit; a storage unit in which the first feature values extracted by the feature value extracting unit are stored; and a fatigue determining unit which determines whether or not the user is fatigued, using the first feature values extracted by the feature value extracting unit, in which the fatigue determining unit compares a first feature value among the first feature values extracted by the feature value extracting unit and at least one of the first feature values stored in the storage unit, to determine whether or not the user is fatigued.

Human fatigue assessment device and human fatigue assessment method

The present invention provides anF-labeled azide compound usable in the Huisgen reaction which enablesF-labeling although only a small quantity of alkyne compound is available as a counterpart substrate, more specifically theF-labeled azide compound enabling the PET to be applied to peptides or oligonucleotides and enabling theF-labeling of any sites of oligonucleotide other than the 5' end or 3&#x2032; end thereof, a reagent forF-labeling, and a method forF-labeling of an alkyne compound using the same.

[object Object]

An inorganic fine particle layer containing inorganic fine particles and a binder component is formed on a surface of a substrate by chemical bonding. The inorganic fine particles are coated with silane monomer each having an unsaturated bond. The content of the binder component is in the range of 0.1% by mass to 40% by mass to the content of the inorganic fine particles.

Antifouling composite material

A label with which labeling is easy when labeling a molecule, i.e., a label that has a high reaction rate upon labeling and that produces a high reaction yield, as well as a precursor for the production of the label are provided. This is achieved by a hexatriene-&#x3b2;-carbonyl compound represented by Formula (I), a hexatriene-&#x3b2;-carbonyl compound represented by Formula (II), a hexatriene-&#x3b2;-carbonyl compound represented by Formula (III) and a hexatriene-&#x3b2;-carbonyl compound represented by Formula (IV). (wherein R, R, R, R, R, X, Xand Z are as defined in the specification)

Hexatriene-&#x3b2;-carbonyl compound

Novel calcium-independent phospholipases A; genes encoding the same; an antibody against them; an inherent promoter or a regulator gene which comprises a base sequence occurring in intron and inducing site-specific expression in response to an external stimulus; a method of expressing a target protein in response to an external stimulus; and an organism having this gene transferred thereinto. Novel calcium-independent phospholipases Ahaving an amino acid sequence represented by SEQ ID NO: 1, 3 or 5 or an amino acid sequence derived from such an amino acid sequence by the substitution, deletion or addition of one or more amino acids; a gene having a base sequence occurring in an intron and being capable of initiating RNA transcription due to an external stimulus such as a stimulus with kainic acid or an electrical stimulus; a method of regulating expression by using the gene; and an organism having the gene transferred thereinto.

Promoter of novel calcium-independent phospholipase A2

The present invention provides a neurodegenerative disease therapeutic agent containing as its active ingredient a (15R)-isocarbacycline derivative indicated by the following formula [I] or a 15-deoxy-isocarbacycline derivative indicated by the following formula [III]:(wherein, Rrepresents a C-Calkylene group, and Rrepresents a hydrogen atom, a C-C, alkyl group or protective group); or,(wherein, Rand Rare the same as those defined in formula [I]).

Neuropathy remedies

The present invention provides an apoptosis inhibitor containing a 15R-isocarbacyclin derivative or a 15-deoxy-isocarbacyclin derivative, which can be manufactured easily and economically by means of chemical synthesis.

Isocarbacyclin derivatives as apoptosis inhibitors

The present invention provides a labelled .beta.-cyano-L-alanine and a .gamma.-cyano-.alpha.-aminobutyric acid, of which cyano group carbon is labelled with radionuclide .sup.11 C or .sup.14 C, or stable isotope .sup.13 C. The present invention also provides a labelled amino acids such as asparagine, asparatic acid, DABA, GABA, glutamine and glutamic acid synthesized by using the labelled .beta.-cyano-L-alanine and the .gamma.-cyano-.alpha.-aminobutyric acid as an intermediate. The labelled amino acids are useful for in vivo imaging of tumors and brain functions.

Labelled compound

To permit detection of trace unstable reaction products to clarify the reaction process of oxygenation, this invenion provides a method of introducing positron nuclide .sup.15 O as an oxygen additive into the reaction system.

Radio-detection method of oxygenation reaction

Growing community of inventors

Osaka, Japan

Yasuyoshi Watanabe